Cite
HARVARD Citation
Gladman, D. et al. (n.d.). FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study. Annals of the rheumatic diseases. p. 673. [Online].